The development of de novo albuminuria during chronic renin–angiotensin system (RAS) suppression is a clinical entity that remains poorly recognized in the biomedical literature. It represents a clear increment in global cardiovascular (CV) and renal risk that cannot be counteracted by RAS suppression. Although not specifically considered, it is clear that this entity is present in most published and ongoing trials dealing with the different forms of CV and renal disease. In this review, we focus on the mechanisms promoting albuminuria, and the predictors and new markers of de novo albuminuria, as well as the potential treatment options to counteract the excretion of albumin. The increase in risk that accompanies de novo albuminuria supports the search for early markers and predictors that will allow practising physicians to assess and prevent the development of de novo albuminuria in their patients.
Translational science in albuminuria: a new view of de novo albuminuria under chronic RAS suppression
- Views Icon Views
- Share Icon Share
Montserrat Baldan-Martin, Elena Rodríguez-Sánchez, Laura González-Calero, Luis M. Ruilope, Gloria Alvarez-Llamas, María G. Barderas, Gema Ruiz-Hurtado; Translational science in albuminuria: a new view of de novo albuminuria under chronic RAS suppression. Clin Sci (Lond) 16 April 2018; 132 (7): 739–758. doi: https://doi.org/10.1042/CS20180097
Download citation file: